ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors

Grant

Date/time Interval

  • February 1, 2016 - January 31, 2018
  • Total Award Amount

  • 18800.00
  • Direct Costs

  • 14921.00
  • Sponsor Award Id

  • Contributor

  • Ana Galtarossa Xavier   Investigator